Meropenem Hikma (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections across several organ systems.

• Complicated intra‑abdominal infections: effective in treating severe intra‑abdominal infections caused by susceptible organisms.
• Complicated urinary tract infections: clears resistant Gram‑negative and Gram‑positive pathogens in the urinary tract.
• Nosocomial pneumonia: combats hospital‑acquired lung infections, including ventilator‑associated pneumonia.
• Meningitis: penetrates the cerebrospinal fluid to eradicate bacterial meningitis agents.
• Septicemia: provides rapid bactericidal activity in bloodstream infections.
• Febrile neutropenia: used empirically to cover high‑risk neutropenic patients with fever.

• Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins (PBPs). This binding blocks the transpeptidation step of peptidoglycan cross‑linking, leading to weakened cell walls, osmotic instability, and ultimately bacterial cell lysis and death. Its broad affinity for multiple PBPs underlies its activity against a wide range of Gram‑negative, Gram‑positive, and anaerobic organisms.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: localized skin erythema or pruritus.
• Headache: transient cranial discomfort.
• Elevated liver enzymes: mild transaminase increases.
• Injection site reactions: pain or erythema at the infusion site.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or high doses.
• Clostridioides difficile‑associated diarrhea: severe colitis risk.
• Anaphylaxis: acute hypersensitivity with respiratory or circulatory collapse.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin detachment.
• Renal toxicity: acute kidney injury in predisposed individuals.
• Thrombocytopenia: marked reduction in platelet count.

Use meropenem with careful clinical monitoring and appropriate patient assessment.

• Renal function: adjust dose in patients with impaired renal clearance.
• Seizure risk: avoid high doses in patients with a history of epilepsy.
• Hypersensitivity: discontinue if signs of an allergic reaction appear.
• Concomitant nephrotoxins: monitor kidney function when used with other nephrotoxic agents.
• Pregnancy and lactation: weigh potential benefits against unknown risks; use only if clearly needed.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: reduces meropenem plasma levels, potentially compromising seizure control.
• Carbapenem‑induced reduction of valproate: may precipitate breakthrough seizures.

Moderate Interactions (Monitor Closely)

• Probenecid: may increase meropenem concentrations, raising toxicity risk.
• Aminoglycosides or vancomycin: combined nephrotoxicity warrants renal function monitoring.
• Loop diuretics: may enhance ototoxic potential when used together.
• Anticoagulants (warfarin): monitor INR as meropenem can affect coagulation parameters.